Thank you for the clarification. Much appreciated.
Regeneron - Internal ________________________________ From: Bauer, Robert <robert.ba...@iconplc.com> Sent: Saturday, January 11, 2025 2:31 AM To: 'Leonid Gibiansky' <lgibian...@quantpharm.com>; Sébastien Bihorel <sebastien.biho...@regeneron.com>; nmusers@globomaxnm.com <nmusers@globomaxnm.com> Subject: RE: [EXTERNAL] Re: [NMusers] MU referencing and time-varying covariates If a covariate varies across records within a subject, NONMEM obtains a simple average among the records and uses this as the covariate value for that subject. Robert J. Bauer, Ph. D. Senior Director Pharmacometrics R&D ICON Early Phase 731 If a covariate varies across records within a subject, NONMEM obtains a simple average among the records and uses this as the covariate value for that subject. Robert J. Bauer, Ph.D. Senior Director Pharmacometrics R&D ICON Early Phase 731 Arbor way, suite 100 Blue Bell, PA 19422 Office: (215) 616-6428 Mobile: (925) 286-0769 robert.ba...@iconplc.com<mailto:robert.ba...@iconplc.com> www.iconplc.com<https://urldefense.com/v3/__http://www.iconplc.com__;!!ODpDvJZr5w!GNRSQC0vmVcClv1zMJgsNsCcNeoMkxqOaEMlRn6_-jHqy6jald8QxKYV1I6AUPX3dritCEex3_fXtP0HHRqN6YOFPjqy8iI$> -----Original Message----- From: owner-nmus...@globomaxnm.com<mailto:owner-nmus...@globomaxnm.com> <owner-nmus...@globomaxnm.com> On Behalf Of Leonid Gibiansky Sent: Friday, January 10, 2025 5:21 PM To: Sébastien Bihorel <sebastien.biho...@regeneron.com>; nmusers@globomaxnm.com<mailto:nmusers@globomaxnm.com> Subject: [EXTERNAL] Re: [NMusers] MU referencing and time-varying covariates Hi Sébastien, As you did these experiments, can you share the results: have you seen any differences in the fit, parameter estimates, precision, convergence speed (number of iteration), and evaluation time for SAEM/IMP (I think, FOCEI does not have this restriction of time-independence even if you use Mu referencing, so results should be identical or very close). As code is encrypted, only Bob can answer the question but my understanding is that some kind of averaging is used to get time independent value of WT that is then used by the SAEM/IMP algorithm for parameter update procedure. As WT changes slowly and not very significantly, it could be hard to see the differences. A more stringent test would be to use time-dependent and strongly influential ADA (0/1): how bad is the incorrect version 1 in this case? Thank you Leonid On 1/10/2025 2:56 PM, Sébastien Bihorel wrote: > > Happy New Year, > > I hope everybody is ready for a great 2025 ! > > I'll start my message/question by defining 2 different ways of coding > a simple power relationship between body weigh on clearance. > > * > Coding 1 > > MU_1 = THETA(1) + THETA(2) * LOG(WGT/70) CL = EXP( MU_1 + ETA(1) ) > > * > Coding 2 > > MU_1 = THETA(1) > CL = EXP( MU_1 + ETA(1) ) * ( WGT/70 )**THETA(2) > > The reference and training materials for NONMEM clearly indicate that > MU variables should be time invariant within occasions and recommend > using coding 2 when body weight is time varying. Nevertheless, it is > possible for an analyst to use coding 1. As far as I can tell from > some limited testing, this is not a "fatal" error. Either with FOCE(I) > or SAEM/IMP, NONMEM reports a warning but performs the model > optimization. The table outputs also report CL as a time varying > variable changing as body weight changes. > > So my questions are the following: when coding 1 is used and body > weight is time varying, what is NONMEM actually doing during model > optimization? Does NONMEM internally create occasions to break the > records by interval of constant body weight and constant MU1? > Alternatively, does NONMEM internally calculate an average of MU1? > Something entirely different? What's the risk taken by an analyst when > using coding 1 versus coding 2? > > Thank you in advance for you input > > > __ > Sébastien Bihorel > Director, Quantitative Pharmacology > +1 914-648-9581 > sebastien.biho...@regeneron.com<mailto:sebastien.biho...@regeneron.com> > > > Regeneron - Internal > > ******************************************************************** > This e-mail and any attachment hereto, is intended only for use by the > addressee(s) named above and may contain legally privileged and/or > confidential information. If you are not the intended recipient of > this e-mail, any dissemination, distribution or copying of this email, > or any attachment hereto, is strictly prohibited. If you receive this > email in error please immediately notify me by return electronic mail > and permanently delete this email and any attachment hereto, any copy > of this e-mail and of any such attachment, and any printout thereof. > Finally, please note that only authorized representatives of Regeneron > Pharmaceuticals, Inc. have the power and authority to enter into > business dealings with any third party. > ******************************************************************** ICON plc made the following annotations. ------------------------------------------------------------------------------ This e-mail transmission may contain confidential or legally privileged information that is intended only for the individual or entity named in the e-mail address. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or reliance upon the contents of this e-mail is strictly prohibited. If you have received this e-mail transmission in error, please reply to the sender, so that ICON plc can arrange for proper delivery, and then please delete the message. Thank You, ICON plc South County Business Park Leopardstown Dublin 18 Ireland Registered number: 145835 ******************************************************************** This e-mail and any attachment hereto, is intended only for use by the addressee(s) named above and may contain legally privileged and/or confidential information. If you are not the intended recipient of this e-mail, any dissemination, distribution or copying of this email, or any attachment hereto, is strictly prohibited. If you receive this email in error please immediately notify me by return electronic mail and permanently delete this email and any attachment hereto, any copy of this e-mail and of any such attachment, and any printout thereof. Finally, please note that only authorized representatives of Regeneron Pharmaceuticals, Inc. have the power and authority to enter into business dealings with any third party. ********************************************************************
